| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B Henry, A R Crossman, J M Brotchi. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental neurology. vol 155. issue 2. 1999-04-07. PMID:10072296. |
the neural mechanisms underlying the generation of dyskinesia following repeated l-3,4-dihydroxyphenylalanine (l-dopa) or dopamine agonist administration in parkinson's disease remain unknown. |
1999-04-07 |
2023-08-12 |
rat |
| B Henry, A R Crossman, J M Brotchi. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental neurology. vol 155. issue 2. 1999-04-07. PMID:10072296. |
we have previously characterized the pharmacology of this enhanced response and have suggested that it is a useful model for the elucidation of the cellular and molecular mechanisms underlying l-dopa- and dopamine agonist-induced dyskinesia. |
1999-04-07 |
2023-08-12 |
rat |
| B Henry, A R Crossman, J M Brotchi. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental neurology. vol 155. issue 2. 1999-04-07. PMID:10072296. |
these studies suggest that anti-parkinsonian treatments which are not associated with an elevation in ppe-b and/or normalize elevated ppe-a precursor expression, such as nmda-receptor antagonists or long-acting dopamine d2 receptor agonists, e.g., cabergoline or ropinirole, may reduce dyskinesia in parkinson's disease. |
1999-04-07 |
2023-08-12 |
rat |
| J M Brotchi. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 13. issue 6. 1999-02-17. PMID:9827609. |
adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in parkinson's disease. |
1999-02-17 |
2023-08-12 |
Not clear |
| J M Brotchi. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 13. issue 6. 1999-02-17. PMID:9827609. |
dyskinesias following long-term dopamine replacement therapy are a major limitation of current treatments for parkinson's disease. |
1999-02-17 |
2023-08-12 |
Not clear |
| O Rascol, C Brefel-Courbon, O Bli. [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients]. Therapie. vol 53. issue 1. 1998-11-03. PMID:9773099. |
new dopaminergic drugs, either with longer elimination half life or with specificity for subtypes of dopamine receptors may allow these dyskinesias to be managed more efficaciously. |
1998-11-03 |
2023-08-12 |
Not clear |
| M Arts, F Bemelmans, A Cool. Activation of N-methyl-D-aspartate receptors in the feline retrorubral nucleus elicits orofacial dyskinesia. European journal of pharmacology. vol 349. issue 1. 1998-09-14. PMID:9669492. |
stimulation of dopamine receptors within a circumscribed subregion of the feline caudate nucleus, that is the anterodorsal part of this nucleus, with dopamine or the dopamine receptor agonist (3,4-dihydroxyphenylimino)-2-imidazoline (dpi) elicits orofacial dyskinesia. |
1998-09-14 |
2023-08-12 |
Not clear |
| G Linazasor. [Dopamine receptors and dyskinesias]. Neurologia (Barcelona, Spain). vol 13. issue 4. 1998-08-07. PMID:9608763. |
[dopamine receptors and dyskinesias]. |
1998-08-07 |
2023-08-12 |
Not clear |
| W Poew. Adjuncts to levodopa therapy: dopamine agonists. Neurology. vol 50. issue 6 Suppl 6. 1998-06-25. PMID:9633683. |
continuous dopaminergic stimulation via subcutaneous dopamine agonist infusions is being investigated as a way to control levodopa-associated peak-dose dyskinesias. |
1998-06-25 |
2023-08-12 |
Not clear |
| R K Pearce, T Banerji, P Jenner, C D Marsde. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement disorders : official journal of the Movement Disorder Society. vol 13. issue 2. 1998-06-15. PMID:9539335. |
we now compare the ability of the novel d2-like selective dopamine agonist ropinirole with that of bromocriptine and l-dopa to induce dyskinesia in mptp-treated common marmosets. |
1998-06-15 |
2023-08-12 |
marmoset |
| R K Pearce, T Banerji, P Jenner, C D Marsde. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement disorders : official journal of the Movement Disorder Society. vol 13. issue 2. 1998-06-15. PMID:9539335. |
however, in common with other dopamine agonists, ropinirole will elicit comparable dyskinesia once l-dopa priming has occurred. |
1998-06-15 |
2023-08-12 |
marmoset |
| R K Pearce, T Banerji, P Jenner, C D Marsde. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement disorders : official journal of the Movement Disorder Society. vol 13. issue 2. 1998-06-15. PMID:9539335. |
these results predict a similar response to ropinirole and other long-acting dopamine agonists in l-dopa-naive patients with pd and emphasize the importance of avoiding initial dyskinesia induction through early use of dopamine agonist drugs. |
1998-06-15 |
2023-08-12 |
marmoset |
| A Colzi, K Turner, A J Lee. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry. vol 64. issue 5. 1998-05-28. PMID:9598668. |
to determine whether continuous waking day dopaminergic stimulation with the dopamine agonist apomorphine can reduce levodopa induced dyskinesias in parkinson's disease |
1998-05-28 |
2023-08-12 |
Not clear |
| S Sarre, D Vandeneede, G Ebinger, Y Michott. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists. Journal of neurochemistry. vol 70. issue 4. 1998-04-23. PMID:9523592. |
the high concentrations of dopamine formed after l-dopa administration may be the cause of dyskinesias or further oxidative stress in parkinson's disease. |
1998-04-23 |
2023-08-12 |
rat |
| A N Sussman, L T Tran-Nguyen, J L Neisewande. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. European journal of pharmacology. vol 337. issue 2-3. 1998-03-03. PMID:9430409. |
chronic reserpine administration produces persistent oral dyskinesia accompanied by severe dopamine depletion in the caudate-putamen. |
1998-03-03 |
2023-08-12 |
Not clear |
| A N Sussman, L T Tran-Nguyen, J L Neisewande. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. European journal of pharmacology. vol 337. issue 2-3. 1998-03-03. PMID:9430409. |
the finding that reserpine-induced oral dyskinesia persisted despite repletion of dopamine in the caudate-putamen suggests that the persistent neuropathological change underlying this behavior occurs in a neural pathway other than the dopaminergic nigrostriatal pathway. |
1998-03-03 |
2023-08-12 |
Not clear |
| W R Gib. Functional neuropathology in Parkinson's disease. European neurology. vol 38 Suppl 2. 1998-01-20. PMID:9387799. |
in parkinson's disease the speed and regional variation in nigrostriatal dopamine loss are associated with a significant pre-symptomatic period, steady rate of progression and a particular topography of l-dopa dyskinesias. |
1998-01-20 |
2023-08-12 |
Not clear |
| A Ekesbo, P E Andrén, L M Gunne, J Tedrof. (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Neuroreport. vol 8. issue 11. 1998-01-08. PMID:9261828. |
we have studied the effects of two d2 dopamine receptor-selective compounds, (-)-osu 6162 and raclopride, on levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp)-lesioned common marmosets (callithrix jacchus). |
1998-01-08 |
2023-08-12 |
monkey |
| F Stocchi, P N Patsalos, A Berardelli, L Barbato, A Bonamartini, M Manfredi, S Ruggier. Clinical implications of sustained dopaminergic stimulation. Clinical neuropharmacology. vol 17 Suppl 2. 1997-12-29. PMID:9358190. |
the postsynaptic dopamine receptors at this point are exposed to a nonphysiologic shift in dopamine level, which may induce changes at the receptor site and contribute to the appearance of "on-off" phenomena and dyskinesias. |
1997-12-29 |
2023-08-12 |
Not clear |
| C D Marsde. Problems with long-term levodopa therapy for Parkinson's disease. Clinical neuropharmacology. vol 17 Suppl 2. 1997-12-29. PMID:9358193. |
dyskinesias in long-term levodopa therapy are poorly understood and difficult to manage, although dopamine agonists can be of some use. |
1997-12-29 |
2023-08-12 |
Not clear |